Ronald Cooper
Algemeen Directeur bij ALBIREO PHARMA, INC.
Vermogen: 28 595 $ op 30-04-2024
Actieve functies van Ronald Cooper
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ALBIREO PHARMA, INC. | Algemeen Directeur | 01-06-2015 | - |
Directeur/Bestuurslid | 01-11-2016 | 02-03-2023 | |
President | 01-06-2015 | 02-03-2023 | |
GENERATION BIO CO. | Directeur/Bestuurslid | 01-03-2021 | - |
Independent Dir/Board Member | - | - | |
Albireo Ltd.
Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Directeur/Bestuurslid | 01-09-2015 | - |
Algemeen Directeur | 01-07-2015 | 01-11-2016 | |
President | 01-07-2015 | 01-11-2016 | |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Directeur/Bestuurslid | - | - |
Algemeen Directeur | - | - | |
President | - | - |
Loopbaan van Ronald Cooper
Eerdere bekende functies van Ronald Cooper
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
GENOCEA BIOSCIENCES, INC. | Directeur/Bestuurslid | 07-06-2016 | 12-04-2021 |
Independent Dir/Board Member | 07-06-2016 | 12-04-2021 | |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-01-2008 | 01-11-2015 |
Opleiding van Ronald Cooper
St. Francis Xavier University | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 5 |
Canada | 2 |
Verenigd Koninkrijk | 2 |
Operationeel
Director/Board Member | 5 |
Chief Executive Officer | 3 |
President | 3 |
Sectoraal
Health Technology | 7 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
GENOCEA BIOSCIENCES, INC. | Health Technology |
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
GENERATION BIO CO. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Albireo Ltd.
Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Health Technology |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Health Technology |
Albireo Pharma, Inc.
Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
- Beurs
- Insiders
- Ronald Cooper
- Ervaring